Anti-Fungal Treatment Study Updated by NexMed (NEXM)
NexMed, Inc. (Nasdaq: NEXM) today announced that it has completed its post hoc analysis of NM100060, the Company's topically-applied treatment for onychomycosis (nail fungus). NexMed seeks to pursue signing a partner for further development of the product.
NM100060 has previously been tested in approximately 2,000 patients enrolled in three Phase 3 clinical studies conducted by Novartis. On July 7, 2009, the Company announced the mutual decision with Novartis to terminate the exclusive, global licensing agreement for NM100060.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
